FDA Accepts Vericel’s BLA for MACI for in Knee Cartilage Defects

FDA has accepted for filing Vericel's Biologics License Application for MACI™ (matrix applied characterized autologous cultured chondrocytes), an investigational autologous cellular product intended to treat adult symptomatic knee cartilage defects.  FDA provided a PDUFA (Prescription Drug User Fee Act) goal date of 1/3/17, and does not plan to...

document icon

You are out of free articles for this month

Subscribe as a Guest for $0 and unlock a total of 5 articles per month.

You are out of five articles for this month

Subscribe as an Executive Member for access to unlimited articles, THE ORTHOPAEDIC INDUSTRY ANNUAL REPORT and more.


Julie Vetalice is ORTHOWORLD's Editorial Assistant. She has covered the orthopedic industry for over 20 years, having joined the company in 1999.

Contact Us